DOJ, HHS-OIG, and CMS Target Wound Care Billing Practices

In 2025, enforcement activity targeting wound care billing and utilization patterns surged to a level not previously seen. The U.S. Department of Justice, the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG), and the Centers for Medicare & Medicaid Services (CMS) have significantly stepped up scrutiny of wound care services, high-cost skin substitutes, and related products under Medicare and Medicaid. These agencies are pursuing false claim enforcement, recoupments, and corporate integrity agreements in cases involving allegedly unnecessary procedures or questionable skin substitute billing practices. Several high-profile settlements and prosecutions tied to wound care grafts and billing irregularities demonstrate the breadth of this heightened enforcement focus. 

Multi-Million-Dollar Settlements Signal Escalating False Claims Act Risk

The featured settlements in 2025 include multi-million-dollar resolutions in alleged false Medicare claims for amniotic and skin substitute products and medically unnecessary debridements. Two owners of several wound graft companies in Arizona pled guilty to a health care fraud conspiracy and were each sentenced to over a decade in prison and ordered to pay nearly $1.2 billion in restitution. They also agreed to a FCA civil liability of over $300 million. In a different FCA settlement, a mobile wound care company and its owner agreed to pay $45 million to resolve allegations of a nationwide scheme to bill Medicare for debridement procedures that were either not medically necessary or had not been performed. Under the settlement, the company also had to enter a five-year Corporate Integrity Agreement which included a corporate monitor.

The U.S. Department of Justice, the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG), and the Centers for Medicare & Medicaid Services (CMS) have significantly stepped up scrutiny of wound care services, high-cost skin substitutes, and related products under Medicare and Medicaid.

‍

These significant resolutions follow a HHS OIG report which identified dramatic spikes in Medicare spending on skin substitutes and warned that certain utilization patterns may indicate fraud, waste, or abuse in the wound care space. CMS has also implemented a final rule changing its skin substitute payment structure and expanded pre-payment review models aimed at curbing potentially inappropriate utilization. 

‍

Apligraf, Dermagraft, Kerecis, and Other CTPs in the Enforcement Spotlight

The DOJ’s 2025 nationwide healthcare fraud takedown is not just another enforcement headline. It is a clear warning to wound care providers that their specialty is now a prime focus of government scrutiny. Advanced wound care, skin substitutes, skin grafts, and high-cost biologics are firmly on the enforcement radar, and regulators and payors are closely examining how products such as Apligraf, Dermagraft, Grafix, TheraSkin, Kerecis, NuShield, and similar cellular and tissue-based products are being used and billed.

Routine billing and documentation issues involving debridement, skin graft placement, and repeated applications of branded skin substitutes have been aggressively pursued for audits and recoupment which can quickly escalate into full-scale investigations by Medicare, Medicaid, and commercial payors such as UnitedHealthcare, Aetna, Cigna, Humana, Blue Cross Blue Shield plans, and major Medicare Advantage organizations. What often begins as a payer medical review can evolve into allegations of lack of medical necessity, improper utilization, or financially motivated product selection.

Why Proactive Legal Strategy Is Critical

The 2025 Healthcare Fraud Takedown makes clear that wound care is now a priority enforcement area for both government agencies and private insurers. Wound care providers who do not proactively address compliance, utilization, and documentation risk around high-cost skin substitutes and skin grafts are placing their revenue, network participation, and professional licenses in jeopardy. Strong internal compliance programs, audit-ready records, careful review of utilization, and legal strategy aligned with the latest enforcement patterns are essential to avoiding costly investigations, recoupments, or even exclusion from Medicare and Medicaid programs. Early involvement of experienced healthcare counsel is essential to protecting your practice in an increasingly aggressive payer and regulatory environment.

How Health Law Alliance Can Help

At Health Law Alliance, we represent wound care providers nationwide in audits, investigations, and enforcement actions brought by Medicare, Medicaid, Medicare Advantage plans, and commercial insurers including UnitedHealthcare, Aetna, Cigna, Humana, and Blue Cross Blue Shield. We regularly handle matters involving debridement, skin grafts, and skin substitute products such as Apligraf, Dermagraft, Grafix, TheraSkin, Kerecis, and other cellular and tissue-based therapies.